

Supplementary A: Supplementary Information Word Files. **File A1:** Author comments concerning the Ovarian data previously published; **File A2:** Patient samples utilized for MSMS; **File A3:** Binary LOOCV test metrics; **File A4:** Concerning Files uploaded to JPost repository; **File A5:** LCQ-ADVANTAGE Instrument Method for MSMS example; **File A6:** LCQ-ADVANTAGE Machine Status Log MSMS example).

Supplementary B: Supplementary Information Excel Files. **File B1:** Sera as used in LOOCV Figures; **File B2:** Master peak areas for each patient De-identified; **File B3:** LOOCV Significant peaks by test and figure; **File B4:** LOOCV results of sera MS peaks; **File B5:** Peak list for MSMS analysis of sera).

Figure S1. LOOCV Analysis of Randomized Groups.

Figure S2. LOOCV Analysis of Stages I or III Ovarian and Endometrial Cancers.

Table S1. Gene IDs and Names of proteins.

Supplementary A: Supplementary Information Word Files. **File A1:** Author comments concerning the Ovarian data previously published; **File A2:** Patient samples utilized for MSMS; **File A3:** Binary LOOCV test metrics; **File A4:** Concerning Files uploaded to JPost repository; **File A5:** LCQ-ADVANTAGE Instrument Method for MSMS example; **File A6:** LCQ-ADVANTAGE Machine Status Log MSMS example).

Supplementary B: Supplementary Information Excel Files. **File B1:** Sera as used in LOOCV Figures; **File B2:** Master peak areas for each patient De-identified; **File B3:** LOOCV Significant peaks by test and figure; **File B4:** LOOCV results of sera MS peaks; **File B5:** Peak list for MSMS analysis of sera).